Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson depreciation and amortization — Consolidated ($M) ($M)
Form 10-Q / 10-K Cash Flows & Segment Note
Latest, Q3 2026
2,117
Period ended Sep 30, 2026
Change on a year earlier
+19.1%
1,777 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Depreciation and amortization — Consolidated ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2,117 | +19.1% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 1,959 | +0.8% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 2,004 | +13.1% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 2,011 | +6.1% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 1,777 | -3.7% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 1,943 | +9.0% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 1,772 | -2.4% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 1,896 | +2.9% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,846 | +0.9% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,782 | -7.9% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,815 | -3.5% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,843 | +4.0% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 1,829 | +8.5% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 1,934 | +10.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 1,880 | +6.3% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 1,772 | -3.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 1,685 | -7.1% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 1,744 | -5.2% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 1,769 | -6.6% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,843 | -5.0% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 1,814 | -0.2% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 1,839 | +6.5% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 1,894 | +8.4% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 1,940 | +6.8% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 1,818 | +5.3% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 1,726 | +1.2% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 1,747 | -0.8% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 1,816 | +4.7% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 1,727 | -0.2% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,705 | -0.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,761 | +0.9% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 1,735 | -7.2% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,731 | +1.2% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 1,717 | +49.3% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 1,746 | +91.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,869 | +77.2% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,711 | +88.4% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 1,150 | +27.8% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 912 | +2.4% | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 1,055 | – | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2016 | Oct 2, 2016 | 908 | – | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jul 3, 2016 | 900 | – | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Apr 3, 2016 | 891 | – | 10-Q FY2016 (XBRL) ↗ |
Breakdown
What makes up depreciation and amortization — consolidated ($m)
- Total segment depreciation and amortization ($M)2,053 · Q3 2026
- Innovative Medicine depreciation and amortization ($M)800 · Q3 2026
- MedTech depreciation and amortization ($M)500 · Q3 2026
- General corporate depreciation and amortization ($M)64 · Q3 2026
- Consumer Health depreciation and amortization ($M) [through FY2023Q2]100 · Q2 2023
Cite this data
StockData. (2026). Johnson & Johnson Depreciation and amortization — Consolidated ($M) ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_da_consolidated
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.